Cytogen Stock Current Valuation
| 217330 Stock | KRW 9,220 230.00 2.43% |
Valuation analysis of Cytogen helps investors to measure Cytogen's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Cytogen's price fluctuation is very steady at this time. Calculation of the real value of Cytogen is based on 3 months time horizon. Increasing Cytogen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cytogen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cytogen Stock. However, Cytogen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9220.0 | Real 9124.5 | Hype 9450.0 | Naive 10324.53 |
The real value of Cytogen Stock, also known as its intrinsic value, is the underlying worth of Cytogen Company, which is reflected in its stock price. It is based on Cytogen's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cytogen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cytogen helps investors to forecast how Cytogen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cytogen more accurately as focusing exclusively on Cytogen's fundamentals will not take into account other important factors: Cytogen Company Current Valuation Analysis
Cytogen's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cytogen Current Valuation | 324.23 B |
Most of Cytogen's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytogen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cytogen has a Current Valuation of 324.23 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology & Medical Research industry. The current valuation for all Republic of Korea stocks is significantly lower than that of the firm.
Cytogen Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cytogen's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cytogen could also be used in its relative valuation, which is a method of valuing Cytogen by comparing valuation metrics of similar companies.Cytogen is currently under evaluation in current valuation category among its peers.
Cytogen Fundamentals
| Return On Equity | -96.72 | |||
| Return On Asset | -0.18 | |||
| Operating Margin | (9.92) % | |||
| Current Valuation | 324.23 B | |||
| Shares Outstanding | 5.63 M | |||
| Shares Owned By Insiders | 39.37 % | |||
| Shares Owned By Institutions | 0.05 % | |||
| Price To Sales | 487.61 X | |||
| Revenue | 347.85 M | |||
| Gross Profit | (129.63 M) | |||
| EBITDA | (5.87 B) | |||
| Net Income | (10.87 B) | |||
| Cash And Equivalents | 30.29 B | |||
| Total Debt | 20.9 B | |||
| Debt To Equity | 0.33 % | |||
| Current Ratio | 16.09 X | |||
| Cash Flow From Operations | (5.23 B) | |||
| Beta | 1.16 | |||
| Market Capitalization | 95.89 B | |||
| Total Asset | 55.53 B | |||
| Z Score | 2.4 | |||
| Net Asset | 55.53 B |
About Cytogen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cytogen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytogen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytogen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Cytogen Stock
Cytogen financial ratios help investors to determine whether Cytogen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cytogen with respect to the benefits of owning Cytogen security.